Merck & Co Inc. Ends Acquisition Talks with Revolution Medicines Valued at $30 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: NASDAQ.COM
- Acquisition Talks Ended: Merck's discussions to acquire Revolution Medicines have ceased due to a failure to agree on a $30 billion valuation, highlighting challenges in biotech mergers and acquisitions.
- Market Reaction: Following the end of negotiations, Revolution's stock plummeted from $117.68 to $95.00 in after-hours trading, a decline of 19.27%, indicating investor uncertainty about the company's future prospects.
- Future Possibilities: Although talks have cooled, there remains a possibility for negotiations to restart or for other suitors to emerge, suggesting ongoing interest in Revolution, particularly with upcoming clinical data releases.
- Competitive Dynamics: Earlier reports indicated AbbVie was in advanced discussions with Revolution, but the company later clarified it is not pursuing a deal, underscoring the competitive landscape and investor interest in the biotech sector.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is 119.53 USD with a low forecast of 95.00 USD and a high forecast of 139.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 109.180
Low
95.00
Averages
119.53
High
139.00
Current: 109.180
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
